Abstract
The variant of concern (VOC) P.1 emerged in the Amazonas state (Brazil) and was sequenced for the first time on 6-Jan-2021 by the Japanese National Institute of Infectious Diseases. It contains a constellation of mutations, ten of them in the spike protein. Consequences of these mutations at the populational level have been little studied so far. From December-2020 to February-2021, Manaus was devastated by four times more cases compared to the previous peak (April-2020). Here, data from the national health surveillance of hospitalized individuals and frequency of the P.1 variant were analysed using a model-based approach to estimate P.1 parameters of transmissibility and reinfection by maximum likelihood. Sensitivity analysis was performed changing pathogenicity and the period analysed (including/excluding the health system collapse period). The new variant transmissibility was found to be about 2.5 times higher (Confidence Interval (95%CI): 2.3–2.8) compared to the previous variant in Manaus. A low probability of reinfection by the new variant (6.4%, 95%CI: 5.7–7.1%).) was estimated, even under initial high prevalence (68%, 95%CI: 63– 74%), by the time P.1 emerged. Consequences of a higher transmissibility were already observed with VOC B.1.1.7 in the UK and Europe. Urgent measures must be taken to control the spread of P.1.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Ethics approval was not necessary because this study analysed only publicly available data, not including identifiable information.
Funding Statement
This work was supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (Finance Code 001 to FMDM, LSF and TPP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (grant number: 315854/2020-0 to MEB, 141698/2018-7 to RLPS, 313055/2020-3 to PIP, 312559/2020-8 to MASMV, 311832/2017-2 to RAK, 305703/2019-6 to AAMS) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (grant number: 2019/26310-2 and 2017/26770-8 to CF, 2018/26512-1 to OC, 2018/24037-4 to SPL and contract number: 2016/01343-7 to RAK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was not necessary because this study analysed only publicly available data, not including identifiable information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used are publicly available. The data sources are described in the manuscript and in supplementary file.
